Daniel Catenacci, MD | Advances in Gastrointestinal Cancer at 2019 ASCO Direct Highlights St. Louis

Daniel Lin, MD | Advances on Gastrointestinal Cancers at 2019 ASCO Direct Highlights PhiladelphiaПодробнее

Daniel Catenacci, MD | Key Point of Gastrointestinal Cancer at 2019 ASCO Direct Highlights St. LouisПодробнее

Daniel Catenacci, MD | Advice on Gastrointestinal Cancer at 2019 ASCO Direct Highlights St. LouisПодробнее

ASCO: Current Data and Outlook for Targeting HER2 in Gastrointestinal CancerПодробнее

Daniel Catenacci, MD, elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020Подробнее

Richard Kim, MD | Advances in Gastrointestinal Cancer at 2019 ASCO Direct Highlights DenverПодробнее

Molecular Testing in Unresectable Biliary Tract Cancer | Daniel Catenacci, MD | ASCO22 GI UpdatesПодробнее

Targeted therapies for gastroesophageal adenocarcinomaПодробнее

Dr. Catenacci on Treatment Selection in Esophagogastric Junction AdenocarcinomaПодробнее

Dr. Catenacci on Results of Margetuximab Plus Pembrolizumab in Gastric/GEJ CancerПодробнее

Dr. Catenacci on the Challenges of Developing Novel Therapies in Gastroesophageal CancerПодробнее

GEJ Adenocarcinoma Treatment Based on ESOPEC Study | Daniel Catenacci, MD | ASCO22 GI Cancer UpdatesПодробнее

Petros Grivas, MD | Advances in Genitourinary Cancer at 2019 ASCO Direct Highlights DenverПодробнее

Daniel Catenacci, MD, discusses margetuximab in the treatment of esophageal and gastric cancerПодробнее

Daniel Catenacci, MD, shares opinion on the role of checkpoint inhibitors for GI malignanciesПодробнее